On February 26, 2026 Evercore ISI maintained Outperform on Edgewise Therapeutics, Inc. and raised its price target to $45, the headline move in the latest EWTX analyst rating updates. The same day Raymond James kept a Strong Buy rating, calling the long-term risk/reward skew attractive. We track both actions because they reinforce positive analyst conviction while leaving near-term share reaction muted. For more on the filings see the Evercore and Raymond James notes on StreetInsider and our EWTX coverage on Meyka AI

EWTX analyst rating: February 26, 2026 summary

Evercore ISI on February 26, 2026 maintained an Outperform rating and raised its price target to $45. StreetInsider: Edgewise Therapeutics (EWTX) PT Raised to $45 at Evercore ISI. Raymond James on February 26, 2026 maintained Strong Buy and reiterated a bullish long-term view. StreetInsider: Raymond James: ‘we continue to see a highly attractive long-term risk/reward skew for EWTX’.

EWTX analyst rating: What Evercore’s change means

Evercore’s move kept the rating steady but raised the EWTX price target to $45, signaling higher confidence in Edgewise’s pipeline and commercial prospects. This change means Evercore foresees more upside potential than before, while still assigning measured execution risk.

EWTX analyst rating: Raymond James outlook and context

Raymond James maintained Strong Buy and emphasized a favorable long-term risk/reward skew, reinforcing its earlier positive stance. That firm did not publish a new price target in the StreetInsider note, but its unchanged rating signals continued conviction among growth-focused analysts.

EWTX analyst rating: Price target, market cap and stock reaction

The updated coverage shows a $45 Evercore target versus Edgewise’s market capitalization of $3,222,635,131. At the time of the StreetInsider releases both entries reported 0.0% ($0.0) price change, indicating little immediate market reaction. Investors should note that rating changes often influence trading only if they differ from consensus or include large target moves.

EWTX analyst rating: Historical coverage and investor implications

Analyst coverage for Edgewise has been limited but positive, with top firms tending to favor the pipeline story over near-term sales data. Investors should view the Evercore and Raymond James ratings as reaffirmations of the growth thesis, not guarantees of performance. Meyka AI rates EWTX with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

Evercore ISI and Raymond James both maintained positive stances on Edgewise Therapeutics on February 26, 2026, with Evercore raising its price target to $45 and Raymond James holding Strong Buy. The twin notes confirm analyst confidence in the company’s development pathway and longer-term upside. Market reaction was muted at release, with StreetInsider entries showing 0.0% ($0.0) change at the time of posting, so investors should weigh these ratings against broader catalysts such as upcoming clinical readouts, revenue trends, and competitive dynamics. Meyka AI rates EWTX with a grade of B, reflecting relative strength versus the S&P 500, sector placement, growth metrics, and consensus analyst views. Use analyst ratings as one input among many; they can guide idea formation but should not replace financial due diligence. These grades are not guaranteed and we are not financial advisors

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.